Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
With the accelerated approval of Brigatinib, and now three approved ALK inhibitors in the 2nd-line setting, how do you decide between these agents?
Should we be routinely sequencing ALK to select an ALK inhibitor with the appropriate efficacy, matched to resistance patterns?
Answer from: Medical Oncologist at Academic Institution
A biopsy should be considered for ALK-rearranged lung cancer patients who previously received crizotinib and developed progression whenever safe and feasible. While most patients with acquired resistance to crizotinib will respond to a next-generation agent, and mutational profiling is not strictly ...
Sign in or Register to read more